Starton Therapeutics Inc. has reported findings from a preclinical efficacy study of STAR-LLD, a continuous delivery system of lenalidomide, in a lenalidomide-resistant animal model. The 28-day efficacy study evaluated STAR-LLD continuous subcutaneous (s.c.) infusion versus intraperitoneal (i.p.) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice.